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A bs tr ac t
Background
Germline truncating mutations in DICER1, an endoribonuclease in the RNase III fam-
ily that is essential for processing microRNAs, have been observed in families with the 
pleuropulmonary blastoma–family tumor and dysplasia syndrome. Mutation carriers 
are at risk for nonepithelial ovarian tumors, notably sex cord–stromal tumors.
Methods
We sequenced the whole transcriptomes or exomes of 14 nonepithelial ovarian tumors 
and noted closely clustered mutations in the region of DICER1 encoding the RNase IIIb 
domain of DICER1 in four samples. We then sequenced this region of DICER1 in ad-
ditional ovarian tumors and in certain other tumors and queried the effect of the 
mutations on the enzymatic activity of DICER1 using in vitro RNA cleavage assays.
Results
DICER1 mutations in the RNase IIIb domain were found in 30 of 102 nonepithelial ovar-
ian tumors (29%), predominantly in Sertoli–Leydig cell tumors (26 of 43, or 60%), in-
cluding 4 tumors with additional germline DICER1 mutations. These mutations were 
restricted to codons encoding metal-binding sites within the RNase IIIb catalytic cen-
ters, which are critical for microRNA interaction and cleavage, and were somatic in all 
16 samples in which germline DNA was available for testing. We also detected muta-
tions in 1 of 14 nonseminomatous testicular germ-cell tumors, in 2 of 5 embryonal 
rhabdomyosarcomas, and in 1 of 266 epithelial ovarian and endometrial carcinomas. 
The mutant DICER1 proteins had reduced RNase IIIb activity but retained RNase 
IIIa activity.
Conclusions
Somatic missense mutations affecting the RNase IIIb domain of DICER1 are common 
in nonepithelial ovarian tumors. These mutations do not obliterate DICER1 function 
but alter it in specific cell types, a novel mechanism through which perturbation of 
microRNA processing may be oncogenic. (Funded by the Terry Fox Research Institute 
and others.)
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Sex cord–stromal tumors and germ-cell tumors account for less than 10% of ovarian cancers.1 Unlike epithelial ovarian 
cancers, both sex cord–stromal tumors and germ-
cell tumors can also occur in the testicle; testicu-
lar germ-cell tumors are the most common cancer 
in boys and men of European descent between 
the ages of 15 and 34 years.2,3 Other than a 
pathognomonic somatic mutation in FOXL2 in adult 
granulosa-cell tumors,4-6 little is known about the 
pathogenesis of ovarian sex cord–stromal tumors 
and germ-cell tumors. Recently, germline muta-
tions in the microRNA processing gene DICER1 
have been reported in probands with pleuropul-
monary blastoma or the related familial tumor 
dysplasia syndrome, known as pleuropulmonary 
blastoma–family tumor and dysplasia syndrome 
(Online Mendelian Inheritance in Man [OMIM] 
number, 601200), which includes cystic nephroma, 
ovarian sex cord–stromal tumor (especially Sertoli–
Leydig cell tumor), and multinodular goiter.7
MicroRNAs (miRNAs) are a functional class of 
noncoding RNA molecules that regulate transla-
tion and degradation of messenger RNA.8,9 MiRNA 
transcripts are processed from hairpin pre-miRNA 
precursors into short miRNA:miRNA* duplexes 
consisting of the miRNA targeting strand and the 
imperfectly complementary miRNA* strand (star 
strand, or inert carrier strand) by Dicer, an endori-
bonuclease with two RNase III–like domains. The 
RNase IIIb domain cuts the miRNA strand, where-
as the RNase IIIa domain cleaves the miRNA* 
strand.10,11 The resultant RNA duplex is loaded 
into the RNA-induced silencing complex (RISC) 
containing an Argonaute protein. The miRNA* 
strand is then removed, leaving the miRNA strand, 
which targets messenger RNAs for degradation or 
interacts with the translation initiation complex to 
inhibit and destabilize translation of the targeted 
messenger RNAs.12,13
The expression levels of Dicer have global ef-
fects on the biogenesis of miRNA, and reduced 
expression correlates with a poor outcome in many 
cancers.7,14-18 In mouse models of cancer, the loss 
of a single Dicer1 allele (haploinsufficiency) reduced 
the time to tumor onset19 or survival time,20 as 
compared with control animals. Experimental data 
support the hypothesis that the pathogenicity of 
aberrations in Dicer function is dependent on the 
cellular context and that the activation or inhibi-
tion of pathways for tissue-specific development 
and differentiation are at least partially controlled 
by specific miRNAs or miRNA families.7,8,21 In 
mouse models with urogenital-specific knockout 
of Dicer1, there is evidence of apoptosis of germ 
cells and Sertoli cells22-24 but no induction of a 
tumorigenic phenotype. Outside the urogenital 
tract, impaired differentiation occurs with Dicer 
loss25-27 but requires a further challenge for on-
cogenesis.19,20
In this study, we report recurrent somatic mis-
sense mutations of DICER1 that implicate a defect 
in miRNA processing, not as a permissive event in 
tumor onset (as might be expected for loss of func-
tion in a tumor suppressor) but rather as an on-
cogenic event in the specific context of nonepithe-
lial ovarian tumors.
Me thods
Experimental Data
The methodologic details of all experiments that 
we conducted are provided in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org. 
Tumor Samples
The 14 discovery samples included juvenile-type 
granulosa-cell tumors, primitive germ-cell tumors 
of the yolk-sac type, and Sertoli–Leydig cell tumors 
from the Children’s Oncology Group at Nation-
wide Children’s Hospital in Columbus, Ohio, and 
the Ovarian Cancer Research Program (OvCaRe) 
tissue bank in Vancouver, British Columbia, Can-
ada. Both resources provide access to samples 
through specific application to studies approved 
by institutional review boards, including next-
generation sequencing studies. We used 411 addi-
tional tumor samples for validation.
Transcriptome, Exome, and Sanger 
Sequencing
We carried out transcriptome sequencing and anal-
ysis as described previously.4,28,29 We performed 
exome capture of genomic coding regions through 
solution hybrid selection.30 Raw data were depos-
ited at the European Genome–Phenome Archive 
(accession number, EGAS00001000135). We per-
formed Sanger sequencing in the region of DICER1 
encoding the RNase IIIb domain in DNA from 
samples in both the discovery and validation series 
and in germline DNA, when available.
Dicer1 Enzyme Assay
We incubated wild-type DICER1 protein, mutants, 
and controls with 5′-32phosphate (32P)–labeled RNA 
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oligonucleotide substrates and analyzed the cleav-
age products by means of gel electrophoresis and 
phosphorimaging.
R esult s
Somatic Mutations in DICER1
Using a combination of whole-transcriptome and 
whole-exome sequencing, we looked for genomic 
aberrations in two Sertoli–Leydig cell tumors, four 
juvenile granulosa-cell tumors, and eight primi-
tive germ-cell tumors of the yolk-sac type (Tables 1 
and 2 in the Supplementary Appendix). We discov-
ered four nonsynonymous missense mutations in 
DICER1 affecting the D1709 residue, one nonsense 
truncating mutation, and one insertion mutation 
that was predicted to result in a frameshift and 
truncation (Fig. 1). All mutations were validated 
by means of Sanger sequencing. The D1709 resi-
due is within a cluster of acidic residues that are 
responsible for metal binding10,11 in the catalytic 
center of the RNase IIIb domain (Fig. 1 in the Sup-
plementary Appendix). Despite adequate sequence 
coverage, we observed no mutations that were pre-
dicted to affect the RNase IIIa domain (Fig. 2 in the 
Supplementary Appendix). Sequence-read data (Ta-
ble 1 in the Supplementary Appendix) and Sanger 
traces from mutant DICER1 samples confirmed 
that all mutations were heterozygous. Copy-num-
ber analysis confirmed that only a single sample, 
PGCTYS-05 with wild-type DICER1, showed hetero-
zygous loss around DICER1 (Fig. 3 in the Supple-
mentary Appendix).
DICER1 Mutations in the Validation Set
The recurrent D1709 mutations in our discovery 
set seemed likely to have an effect on cleavage of 
miRNAs and metal (Mg2+/Mn2+) binding and are 
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Figure 1. Mutations in DICER1.
The 27 exons of DICER1 are represented as numbered gray boxes above a diagram of the gene encoding the protein (shown below in 
blue), with the two catalytic RNase III domains shown in yellow. Active sites are indicated by a pink line, and metal-binding sites are indi-
cated by a purple line, with the polybromo (PBRM) domain in purple. The abbreviation dsRNA denotes double-stranded RNA, PAZ Piwi 
Argonaut and Zwille domain, and UTR untranslated region. The mutations that are listed above the exons were identified on whole-tran-
scriptome or whole-exome sequencing of 14 samples in the discovery set, and those listed below were identified through targeted 
Sanger-sequencing analysis of 101 samples of nonepithelial ovarian tumor, 39 samples of nonepithelial testicular tumor, and 5 samples 
of embryonal rhabdomyosarcoma. All recurrent somatic mutations were missense mutations in codons encoding metal-binding sites in 
the RNase IIIb domain (magnified region). Seven of the samples were found to carry another DICER1 mutation (indicated with a slash) 
in addition to a hot-spot mutation.
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thus potentially pathogenic.10,11 We performed 
Sanger sequencing encompassing the regions en-
coding all four metal-binding residues within the 
RNase IIIb domain in a validation set that includ-
ed 101 additional nonepithelial ovarian tumors 
(Table 1, and Tables 3, 4, and 5 in the Supplemen-
tary Appendix). We also screened 39 testicular 
tumors to determine whether they harbored the 
same mutations. Among the nonepithelial ovarian 
tumor types that were screened, mutations affect-
ing any one metal-binding residue were present, 
with the highest prevalence in Sertoli–Leydig cell 
tumors: 26 of 43 (60%) of these tumors harbored 
a mutation. We designated these mutations affect-
ing RNase IIIb metal-binding residues as hot spots. 
Apart from ovarian sex cord–stromal tumors and 
germ-cell tumors, 1 of 14 single, developmentally 
related, nonseminomatous testicular germ-cell tu-
mors harbored a D1709N mutation (Table 3 in the 
Supplementary Appendix). To determine whether 
these mutations occur in other cancers with a so-
called primitive phenotype, we analyzed 5 embry-
onal rhabdomyosarcomas; 2 of these tumors had 
hot-spot mutations, 1 of which occurred in a patient 
with a previously described germline mutation.31
We found hot-spot mutations in 33 of 159 tu-
mors in the discovery and validation sets com-
bined, including ovarian, testicular, and embryonal 
rhabdomyosarcoma tumor types. Among these 
mutations, the most prevalent were the 17 muta-
Table 1. Prevalence of Somatic Hot-Spot Mutations Affecting the RNase IIIb Domain of DICER1 in Nonepithelial 
Ovarian Tumors.*
Tumor Type Frequency
Changes in Coding 
Sequence
No. of  
Mutations Predicted Amino Acid Changes
no./total no. (%)
Sex cord–stromal tumor
Sertoli–Leydig cell tumor 26/43 (60) c.5113G→A 5 p.Glu1705Lys (E1705K)
c.5125G→A† 10 p.Asp1709Asn (D1709N)
c.5126A→G 1 p.Asp1709Gly (D1709G)
c.5127T→A 2 p.Asp1709Glu (D1709E)
c.5428G→C 1 p.Asp1810His (D1810H)
c.5428G→T 2 p.Asp1810Tyr (D1810Y)
c.5428G→A† 1 p.Asp1810Asn (D1810N)
c.5437G→C 2 p.Glu1813Gln (E1813Q)
c.5438A→G 1 p.Glu1813Gly (E1813G)
c.5437G→A 1 p.Glu1813Lys (E1813K)
Juvenile granulosa-cell tumor 1/14 (7) c.5126A→G 1 p.Asp1709Gly (D1709G)
Adult granulosa-cell tumor 0/15
Germ-cell tumor
Primitive germ-cell tumor
Yolk sac 2/15 (13) c.5125G→A 1 p.Asp1709Asn (D1709N)
c.5127T→A 1 p.Asp1709Glu (D1709E)
Dysgerminoma 0/1
Mixed 0/1
Teratoma
Immature 0/5
Mature 1/8 (12) c.5428G→T† 1 p.Asp1810Tyr (D1810Y)
* Listed is the frequency of hot-spot mutations in specimens in which both the 1700 and 1800 amplicons were success-
fully sequenced, unless otherwise indicated.
† One specimen in this group contained a somatic mutation at the indicated position but could not be assessed for mu-
tations affecting all four RNase IIIb metal-binding sites.
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tions affecting D1709. We confirmed that muta-
tions were somatic in 16 cases for which we had 
corresponding germline DNA. We attempted to 
assess all hot-spot regions by performing Sanger 
sequencing of two independent amplicons span-
ning the metal-binding residues (for details, see 
the Methods section in the Supplementary Ap-
pendix). However, because of poor preservation 
of DNA in formalin-fixed, paraffin-embedded 
material, in some instances we could sequence 
only a single amplicon (4 mutation-positive sam-
ples and 18 mutation-negative samples) (Table 3 
in the Supplementary Appendix). In cases in which 
both amplicon regions were successfully se-
quenced, mutations affecting any one RNase IIIb 
metal-binding residue were mutually exclusive 
with mutations affecting any other IIIb metal-
binding residue (P<0.01 by Fisher’s exact tests) 
(Fig. 4 in the Supplementary Appendix). We ob-
served no mutations affecting the metal-binding 
regions of the RNase IIIa domain, despite tar-
geted sequencing of 4 samples that were positive 
for an RNase IIIb mutation and 9 samples that 
were mutation-negative. Immunohistochemical 
analysis did not provide a proxy for hot-spot 
mutation status, since all tumors were positive 
for DICER1 expression (Fig. 5 in the Supplemen-
tary Appendix).
The DICER1 hot-spot mutations are not present 
in the 1000 Genomes Project data or the public-
data repository of the Cancer Genome Atlas con-
sortium. No recurrent DICER1 mutations have been 
reported in the mutation database of the Cata-
logue of Somatic Mutations in Cancer (COSMIC), 
in which 4 of 938 cancers have somatic mutations 
but none in the RNase IIIb hot spots or RNase IIIa 
equivalents.32 Moreover, these mutations were not 
observed in any of the more than 1000 cancer-
sequencing libraries that we studied or in 15 adult 
granulosa-cell tumors with FOXL2 mutations 
from our validation cohort. On the basis of re-
ported DICER1 dysfunction in epithelial ovarian 
cancers,14 we further analyzed a series of 266 epi-
thelial ovarian and endometrial cancers and ob-
served a somatic hot-spot mutation (c.5676G→A, 
encoding an E1813G substitution) in a single 
ovarian carcinosarcoma (Table 4 in the Supple-
mentary Appendix).
Compound DICER1 Mutations
Across our discovery and validation series, seven 
samples had a hot-spot mutation and an addi-
tional germline or somatic DICER1 mutation (Ta-
ble 2, and Table 3 in the Supplementary Appen-
dix). To show that the specific hot-spot DICER1 
somatic mutation was a separate hit on a differ-
ent allele from the germline mutation, we cloned 
and sequenced complementary DNA (cDNA) from 
sample SLCT-19, which had a germline DICER1 
deletion (5018-5021delTCAA). The primers for the 
Table 2. Patients with a Hot-Spot Mutation and an Additional Germline or Somatic DICER1 Mutation.*
Patient No. Hot-Spot DICER1 Mutation Additional DICER1 Mutation
Truncating  
Mutation
Mutations in  
Cis or Trans
ERMS-05 c.5113G→A (E1705K) c.3907_3908delCT (germline)31 Yes Not assessed
PGCTYS-02 c.5127T→A (D1709E) c.5492G→A (somatic) Yes Trans
SLCT-01 c.5125G→A (D1709N) c.3237_3238insCCAGCAT (somatic) Yes Trans
SLCT-08 c.5113G→A (E1705K) c.3611_3616delACTACAinsT (germline)31 Yes Not assessed
SLCT-19 c.5125G→A (D1709N) c.5018_5021delTCAA (germline)33 Yes Trans
SLCT-20† c.5125G→A (D1709N) c.2825delC (germline) Yes Trans
SLCT-26 c.5437G→A (E1813K) c.2457C→G (germline)‡33  No‡ Not assessed
* ERMS denotes embryonal rhabdomyosarcoma, PGCTYS primitive germ-cell tumor of the yolk-sac type, and SLCT 
Sertoli–Leydig cell tumor.
† This patient presented with a family history of nonepithelial ovarian cancer on the maternal side and was therefore 
screened for germline mutations in DICER1. A germline DICER1 mutation was identified in the proband, but the mutation 
was not found in her mother, and her father’s DNA was not available for testing (see also Fig. 4A in the Supplementary 
Appendix).
‡ This mutation causes a splice change and a 21-bp in-frame deletion within the region encoding the PAZ domain. The 
effect of this change is unknown.
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reverse-transcriptase–polymerase-chain reaction 
(RT-PCR) assay were chosen to allow capture of 
both the germline and somatic changes in a single 
amplicon, should the two changes exist in cis with 
one another (Fig. 2). Only the allele with the hot-
spot mutation was observed, a finding consistent 
with a lymphoblastoid cell line derived from the 
same person in which transcripts containing the 
germline variant have been shown to undergo 
nonsense-mediated decay of messenger RNA.33 
Using this RT-PCR strategy, we further showed 
that hot-spot mutations in three other samples 
were in trans with a separate DICER1 mutation, 
and expression of the allele with the hot-spot 
mutation was predominant (Table 2, and Fig. 6 in 
the Supplementary Appendix). Although it is pos-
sible that mutation of the non–hot-spot allele was 
present in other tumors from this study, because 
of the generally poor quality of DNA from forma-
lin-fixed, paraffin-embedded samples, screening 
of the entire DICER1 sequence was not performed.
Functional Characterization of Dicer1 
Mutants
We carried out RNA cleavage assays to compare the 
activity of DICER1 proteins containing the hot-
spot D1709N, D1709E, and E1705K substitutions 
with that of wild-type and control samples, includ-
ing a D1709A mutant with greatly reduced RNase 
IIIb activity that shows total loss of DICER1 func-
tion only if a substitution in the RNase IIIa domain 
is also present10,11 (Fig. 3). Wild-type DICER1 (in-
cluding ectopic, endogenous, and commercially 
obtained forms) generated products of 18 and 22 
nucleotides (Fig. 3B, and Fig. 7 in the Supplemen-
tary Appendix). These products correspond to 
those of enzymatic cleavage that produce a ma-
ture miRNA duplex (Fig. 3A), whereas the D1709A 
enzyme generated only the 18-nucleotide prod-
uct, as expected.10,11 This finding indicates that 
the 22-nucleotide band is derived from activity at 
the RNase IIIb site, whereas the 18-nucleotide 
band is related to activity at the RNase IIIa site. 
The hot-spot mutant DICER1 proteins yielded 
markedly low levels of the 22-nucleotide product 
and substantial levels of the 18-nucleotide product, 
suggesting that, like the D1709A mutation, the 
D1709N, D1709E, and E1705K substitutions result 
in reduced RNase IIIb activity but retention of 
RNase IIIa activity.
B
A
5125G Site Germline DNA 
5125G→A Tumor DNA  
5018-5021delTCAA Germline DNA 
5018-5021delTCAA Tumor DNA 
5018-5021delTCAA
(not observed) 
5125G→A  
Figure 2. Germline Mutations of DICER1 in Trans with Somatic Hot-Spot 
Mutations.
In Panel A, a sample from a patient with familial multinodal goiter and a 
Sertoli–Leydig cell tumor (SLCT-19) shows both a germline and somatic hot-
spot DICER1 mutation. The subpanels at left show sequence traces from 
germline (top) and tumor (bottom) samples at the site of the germline DICER1 
mutation (5018-5021delTCAA, blue arrows). The subpanels at right show the 
position of the hot-spot somatic DICER1 mutation (c.5125G→A, D1709N, 
red arrow) from germline (top) and tumor (bottom) samples. In Panel B,  
a sequence trace from cloned complementary DNA in sample SLCT-19 en-
compasses both the germline mutation region (5018-5021delTCAA) and 
the somatic hot-spot mutation. Consistent with nonsense-mediated mes-
senger RNA decay noted in lymphoblastoid cells from this patient, the 
germline change was also undetectable in all 98 cloned RT-PCR products 
from the tumor, indicating the absence of expression of this allele (see also 
Fig. 6 in the Supplementary Appendix). All tumors, including SLCT-19, were 
positive for DICER1 expression on immunohistochemical staining (see also 
Fig. 5 in the Supplementary Appendix).
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Preliminary analysis of miRNA expression in 
four Sertoli–Leydig cell tumors with DICER1 hot-
spot mutations had similar overall mature or pro-
cessed miRNA expression levels as a Sertoli–Leydig 
cell tumor with no mutation in DICER1 (Fig. 8 in 
the Supplementary Appendix). Three of these Ser-
toli–Leydig cell tumors had second-allele non–hot-
spot mutations, two of which were known to be 
truncating (Table 2). Thus, miRNA processing in 
the latter two Sertoli–Leydig cell tumors probably 
occurs through the hot-spot mutant DICER1, in 
which case tumors with mutant and nonmutant 
versions of DICER1 have similar levels of miRNA-
processing activity.
Discussion
The hot-spot DICER1 mutations that we report here 
are predominantly restricted to a specific subset of 
nonepithelial ovarian tumors and are highly prev-
alent (60%) in Sertoli–Leydig cell tumors. We also 
observed hot-spot mutations in a single high-grade 
ovarian carcinosarcoma, one testicular germ-cell 
tumor, and two embryonal rhabdomyosarcomas. 
The presence of these recurrent mutations in tu-
mors that have an embryonal or primitive ap-
pearance suggests that their pathogenicity may be 
restricted to specific cell types or developmental 
settings.
Generally, though, somatic mutations in DICER1
in patients with cancer are rare. A survey of can-
cer cell lines showed that 4 of 781 had truncating 
changes in DICER1.34 It is not clear whether these 
mutations were germline or somatic, but all oc-
curred in microsatellite-unstable lines, suggesting 
limited relevance to carcinogenesis. Somatic muta-
tions in DICER1 (albeit not the hot-spot mutations 
described here) have been reported in a single pa-
tient with prostate cancer35 and in two patients 
with epithelial ovarian cancers.14
Germline truncating DICER1 mutations have 
been reported in children with pleuropulmonary 
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(wt) D1709, D1709A, D1709E, D1709N, and E1705K indicate affinity-purified DICER1. Controls include empty vector, mock reaction (sub-
strates only in Dicer enzyme assay buffer), commercial wild-type DICER1, and endogenous DICER1 (immunopurified with an anti–DICER1 
antibody). The lane that is labeled pre-miRNA/miRNA* shows pre-miRNA and pre-miRNA* substrates as markers, and the lanes that 
are labeled pre-miRNA ladder and pre-miRNA* ladder show hydrolysis ladders of those substrates. The blue and green arrows mark the 
positions of the domain cleavage products of RNase IIIb (approximately 22 nucleotides) and RNase IIIa (approximately 18 nucleotides), 
respectively, when DICER1 binds the natural pre–Let7a-3 substrate from the left side, as in Panel A. The full gel images and additional 
controls are shown in Figure 7 in the Supplementary Appendix.
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blastoma or a family history of the disease and 
related disorders, including families with Sertoli–
Leydig cell tumors7 or ovarian sex cord–stromal 
tumors with or without a history of pleuropulmo-
nary blastoma.36 Among 823 patients with a vari-
ety of primitive tumors, there was a low prevalence 
of germline DICER1 mutations that are likely to 
cause loss of function.34 None of these germline 
mutations involved the hot-spot locations that we 
report here or appeared to cluster within narrow 
regions. Retention of the wild-type DICER1 allele 
has been reported in the context of these germline 
loss-of-function mutations in all cases in which 
loss-of-heterozygosity studies were performed.7 It 
is possible that undetected hot-spot mutations 
were present on the ostensibly wild-type allele in 
these tumors.
The recurrent and focal nature of the mutations 
and their restriction to nonepithelial ovarian tu-
mors suggest a common oncogenic mechanism 
associated with a specific altered DICER1 function 
that is selected during tumor development in these 
cell types. This hypothesis is supported by several 
other observations. First, the in vitro biochemical 
data support impaired RNase IIIb activity and re-
tention of RNase IIIa activity in tumors with hot-
spot mutations. The fact that the RNase IIIa do-
main appears to be unaffected by mutations in the 
tumors that have been screened so far suggests 
that biologic activity in tumors with hot-spot muta-
tions could be associated with the retained activity 
of the RNase IIIa site or the RISC loading function 
of DICER1. Second, DICER1 protein with hot-
spot mutations appears to be capable of miRNA 
processing. We observed a second mutation in 
seven tumors with hot-spot mutations, and in six 
of these samples, the non–hot-spot mutated al-
lele was predicted to be null. Thus, any DICER1-
associated miRNA biogenesis in these six tumors 
was probably due to the activity of DICER1 with a 
hot-spot mutation. Although a global reduction 
in miRNA expression is one potential effect of the 
hot-spot mutation, our analysis suggests that a 
total loss of miRNA biogenesis is highly unlikely.
Finally, DICER1 expression in tumors with hot-
spot mutations argues against a role for DICER1 
as a classic two-hit tumor suppressor. The local-
ized and focal pattern of mutation is typical of 
dominantly acting oncogenes, like KRAS and BRAF. 
The absence of loss of heterozygosity that is seen 
in association with germline DICER1 mutations 
provides further evidence against a role for DICER1 
as either a haploinsufficient or a two-hit reces-
sive tumor suppressor. Our findings suggest that 
DICER1 alleles with hot-spot mutations produce 
viable protein. The hot-spot mutations appear to 
represent a new class in which the loss of the 
wild-type allele may occur in tandem with the 
retention of a hot-spot mutant DICER1 protein.
We hypothesize that an oncogenic miRNA pro-
file is derived from altered DICER1 activity in the 
RNase IIIb domain. Furthermore, such activity 
may result in a positive bias toward the processing 
or selection of the RNase IIIa–processed strand of 
the miRNA duplex (the miRNA* strand), which is 
consistent with the finding that the ability of 
DICER1 to load miRNA into RISC does not depend 
on the integrity of its RNase III domains.37 Recent 
studies suggest that miRNA* species may be im-
portant in gene regulation rather than simply be-
ing an inert strand.38,39 This hypothesis is con-
sistent with the known importance of specific 
miRNAs in cell differentiation and cell-fate de-
termination, although the mechanisms by which 
RNase IIIb hot-spot mutations affect miRNA pro-
cessing or RISC loading in the context of cancer 
development warrants further investigation. We 
conclude that in a range of nonepithelial ovarian 
cancers, and potentially other cancers, aberrant 
miRNA processing resulting from DICER1 hot-spot 
mutations is a key oncogenic event. 
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